In an interview with San Jose Business Journal Squire Sanders partner Maureen Bennett explains the risks US companies face if setting up clinical trials overseas or selling prescription drugs in international markets. She also speaks about the various legal and regulatory issues for overseas trials.
Maureen co-chairs Squire Sanders' Global Life Sciences Industry Group. She represents pharmaceutical, medical device and biotechnology companies in connection with a wide range of commercial and regulatory issues and also assists life sciences companies with cross-boundary acquisitions and investment transactions.
You can see the full interview here.